Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Horiba Medical (Kyoto, Japan) presented its high-end hematology solutions alongside different configurations of laboratory organization as well as its comprehensive range of hemostasis and clinical chemistry instruments at MEDLAB Middle East 2021.

On display at the event were the Yumizen H2500, Yumizen SPS and Yumizen P8000 - the new generation of Horiba automated hematology analyzers that answers customers’ expectations of solid and reliable diagnostic technology as well as rapid and consistent results. More...
Some of their features include a real throughput of 120 samples per hour for CBC-DIFF, NRBC included, sampling volume of 110μl (CBC, DIFF, BF) and 75μL (Slide), only six reagents, automatic 360° rotative sample mixing for perfect homogeneity, two PLT technologies - Impedance & Optical extinction – and three WBC counts in CBC and differential modes. All the instruments are compatible with the HELO Solution (HORIBA Evolutive Laboratory Organization).

Horiba also showcased its Yumizen H500 and H550 analyzers that have been designed to deliver a rapid and comprehensive hematology report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, urgent manual mode; and for running samples through multi analysis modes and sampling. Based on color codes, minimum operation and quality flagging messages, the ergonomics of the new Yumizen H500 and H550 are perfectly dedicated to users of small size laboratories such as emergency rooms or physician office labs. With its menu of extensive parameters and enhanced clinical performances the new Yumizen H500 and H550 analyzers are capable of meeting the demands of a variety of clinical lab environments and clinical settings: routine hematology, satellites labs, oncology care, blood banks.

In addition, Horiba highlighted the Microsemi LC-667G hematology analyzer featuring the exclusive concept of simultaneous blood analysis + CRP measurement, along with data management. It is the first hematology analyzer to offer malaria screening flag combined with CBC count. The Malaria screening flag with high sensitivity alerts the physician about suspicion of malaria infection and is available in CBC or CBC+CRP routine use without any specific reagent or dedicated mode. The added value is part of a complete solution of using the MicrosEmi CRP as an infectious differentiator.

Related Links:
Horiba Medical


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Urine Analyzer
respons® UDS100
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.